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eukocyte Count and Coronary Heart Disease
mplications for Risk Assessment
ohammad Madjid, MD,*† Imran Awan, MD,*† James T. Willerson, MD,*† S. Ward Casscells, MD*†‡
ouston, Texas
Inflammation is a key feature of atherosclerosis and its clinical manifestations. The leukocyte
count is a marker of inflammation that is widely available in clinical practice. This paper
reviews the available epidemiologic evidence for a relationship between the leukocyte count
and coronary heart disease (CHD). Numerous epidemiologic and clinical studies have shown
leukocytosis to be an independent predictor of future cardiovascular events, both in healthy
individuals free of CHD at baseline and in patients with stable angina, unstable angina, or a
history of myocardial infarction. This relationship has been observed in prospective and
retrospective cohort studies, as well as in case-control studies. It is strong, consistent,
temporal, dose-dependent, and biologically plausible. The relationship persists after adjust-
ment for multiple CHD risk factors, including smoking. Elevated differential cell counts,
including eosinophil, neutrophil, and monocyte counts, also predict the future incidence of
CHD. Leukocytosis affects CHD through multiple pathologic mechanisms that mediate
inflammation, cause proteolytic and oxidative damage to the endothelial cells, plug the
microvasculature, induce hypercoagulability, and promote infarct expansion. In summary,
leukocytosis has been consistently shown to be an independent risk factor and prognostic
indicator of future cardiovascular outcomes, regardless of disease status. The leukocyte count
is inexpensive, reliable, easy to interpret, and ordered routinely in inpatient and outpatient
settings. However, its diagnostic and prognostic utility in CHD is widely unappreciated.
Further studies are needed to assess the true impact of leukocytosis on CHD, compare it with
other inflammatory markers such as C-reactive protein and lipoprotein phospholipase A2
levels, and promote its use in CHD prediction. (J Am Coll Cardiol 2004;44:1945–56)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.056© 2004 by the American College of Cardiology Foundation
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tardiovascular disease (CVD) is the leading cause of death
n the Western world (1). One of its most insidious forms is
oronary heart disease (CHD) due to atherosclerosis (2).
lthough many risk factors for CHD have been identified,
hey do not fully account for all cases of the disease. Thus,
he search is underway for additional biologic markers and
specially inflammatory markers. The interest in inflamma-
ory markers is warranted for several reasons. Various types
f inflammatory cells, including monocytes, lymphocytes,
osinophils, and neutrophils, have been implicated in CHD
3,4). Numerous epidemiologic and clinical studies (re-
iewed in Tables 1 to 3) have shown the leukocyte count to
e an independent risk factor for CHD, a risk factor for
uture cardiovascular events in individuals apparently with-
ut CVD, and a prognostic marker of future events in
atients who already have CVD (5). This review discusses
he relationship between leukocyte count and CHD in
rospective, retrospective, and case-control studies, as well
s the implications for clinical risk assessment and progno-
is. We searched for the relevant studies using online
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ccepted July 13, 2004.atabases (with major emphasis on PubMed), reference
ections of major textbooks, and personal communication
ith experts in the field. We also searched through the
eferences of all the studies found from previous sources to
ocate additional references that may be useful for this
eview. To avoid a selection bias, we made every effort to
nd and discuss studies with negative findings. To ensure
he quality of our data, we limited our review to the studies
ublished as full text in peer-reviewed journals.
NFLAMMATION AND ATHEROSCLEROSIS
orrelation of the leukocyte count with CHD and investi-
ations into the utility of the leukocyte count as a risk factor
nd prognostic indicator in patients with CHD are consis-
ent with the current concept that atherosclerosis is an
nflammatory disease (2). According to this concept, mono-
ytes are recruited from the peripheral blood into the vessel
all after endothelial injury. The recruited monocytes dif-
erentiate into macrophages that phagocytose lipids and
ecrete metalloproteinase enzymes, such as elastase and
ollagenase, within the atherosclerotic lesion (2,6,7). In
ddition, neutrophils and mast cells that also secrete or
nduce degradative proteases begin to accumulate in the
laque (8–10). Over time, the recruitment and accumula-
ion of inflammatory cells increase the lipid and inflamma-
ory cell content of the plaque and cause extensive neovas-
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Leukocyte Count and CHD November 16, 2004:1945–56ularization of involved adventitia and intima (11). The
therosclerotic plaque becomes more vulnerable to rupture,
eading to cardiovascular events. When plaque rupture does
ccur, it is usually followed immediately by mural or
cclusive coronary thrombosis and dynamic vasoconstriction
n exposed intimal tissue in or near areas of luminal
nflammation (12,13).
OTAL LEUKOCYTE COUNT AS A
ISK FACTOR IN SUBJECTS FREE OF CHD
he leukocyte count has been correlated with CHD since
he 1920s (14). Over the last several decades, an increasing
umber of prospective studies conducted in CHD-free
opulations have shown a clear and positive correlation
etween the leukocyte count and risk of CHD (Table 1)
15–19). The correlation appears to persist even after
djustment for other risk factors (20–22). It also appears to
e especially strong in individuals who smoke, despite some
vidence to the contrary from a study done in elderly
etherlanders (23). The Evaluation of c7E3 Fab in the
revention of Ischemic Complications (EPIC) trial (24)
evealed a correlation between baseline leukocyte count and
he incidence of myocardial infarction (MI) after elective
ercutaneous coronary intervention.
Two case-control studies in disease-free subjects (25,26)
onfirmed the correlation between leukocyte count and
HD. One of these studies (25), which evaluated gender-,
ge-, and risk-matched subjects, found that the mean
eukocyte count was higher in patients than in control
ubjects (8,000/mm3 vs. 7,500/mm3). The other study,
hich used a cohort of dyslipidemic men from the Helsinki
eart Study of coronary atherosclerosis primary prevention,
ound leukocyte counts to be higher in patients than in
ontrols at baseline before admission. In addition, smokers
ith elevated white blood cell (WBC) counts had a higher
elative risk for disease than non-smokers. As discussed
ater, the WBC count is usually higher in smokers; however,
heir effect is mostly additive, as WBC is an independent
isk factor for CHD.
Retrospective studies in disease-free subjects have also
orrelated the leukocyte count and CHD. A large, retro-
pective five-year cohort study (27) showed not only that
Abbreviations and Acronyms
BMI  body mass index
CAD  coronary artery disease
CHD  coronary heart disease
CK  creatine kinase
CRP  C-reactive protein
CVD  cardiovascular disease
IL  interleukin
MI  myocardial infarction
UA  unstable angina
WBC  white blood celligh leukocyte counts at baseline correlated with the devel- bpment of acute coronary syndromes, but also that baseline
eukocyte counts were higher in diseased patients than in
atients who had no significant CHD or stable angina.
OTAL LEUKOCYTE COUNT AS A
ROGNOSTIC INDICATOR IN SUBJECTS WITH CHD
table CHD. Several studies have shown a strong link
etween leukocyte count and prognosis in patients who have
table CHD after a previous MI. The leukocyte count was
trongly associated with the prognosis of patients who have
ad an MI within the previous three months (28). In the
rst Persantin-Aspirin Re-Infarction Study (PARIS-1)
29), the baseline leukocyte count was strongly associated
ith coronary event recurrence and total mortality 2 to 60
onths after MI, even after adjustment for other variables,
ncluding smoking. In a study of patients who had angio-
raphically documented coronary artery stenosis (30), both
he leukocyte count and neutrophil count at baseline corre-
ated with the number and extent, severity, and location
Gensini index) of coronary stenoses and survival. Another
tudy (31) found that patients with angiographically docu-
ented coronary artery disease (CAD) had higher leukocyte
ounts than patients without it. The same study also
ndicated that, after adjustment for age, gender, cholesterol,
riglyceride level, and smoking, the leukocyte count was an
ndependent marker of CHD severity (i.e., diameter steno-
is). In a study of patients who have had an acute MI within
he previous six months (32), high leukocyte counts were
ssociated with an increased risk of re-infarction or death,
ven after adjusting for confounding risk factors.
cute MI or unstable angina (UA). In a study that
orrelated hemostatic variables with mortality in patients
ith acute MI (33), leukocyte counts at presentation were
ignificantly higher in patients with acute MI, as opposed to
A, in patients with transmural infarcts, as opposed to
ubendocardial infarcts, and in patients with radiographi-
ally documented left ventricular failure, as opposed to no
eart failure. In addition, leukocyte counts strongly corre-
ated with increased mortality at six weeks and one year. In
study of the relationship between leukocyte count and
n-hospital mortality after MI (34), the case-fatality rate
ncreased markedly with each incremental (1 SD) increase
n leukocyte count. In one study of patients with acute MI
r high-risk UA pectoris (35), mortality was especially
igher among patients who had leukocyte counts 10,000.
arron et al. (36) utilized the Cooperative Cardiovascular
roject database and stratified patients with acute MI into
uintiles by leukocyte count and found that patients in the
ighest quintile were three times more likely to die early
han patients in the lowest quintile. In the Treat Angina
ith Aggrastat Plus Determine Cost of Therapy with an
nvasive or Conservative Strategy–Thrombolysis In Myo-
ardial Infarction-18 (TACTIS–TIMI-18) trial of patients
ith UA or non–ST-segment elevation MI (37), high
aseline leukocyte counts were associated with poorer reper-
Table 1. Studies Correlating Leukocyte Count and Coronary Heart Disease in Subjects Free of Disease at Baseline
Study
Type Study (Ref.) Sample Size
Follow-Up
(yrs) Clinical End Points Risk Estimate* 95% CI p Value Setting Gender
Years of
Enrollment
Leukocyte Count
Cutoff Values
P Zalokar et al. (15) 7,206 6.5 Fatal/nonfatal MI 4.5 2.5–7.8 0.01 France M 1967–1972 6,000 vs. 9,000
P Grimm et al. (16) 6,222 7 CHD death 1.98 1.2–3.4 0.001 U.S. M 1973–1982 6,000 vs. 7,700
P Grimm et al. (16) 6,222 7 CHD death/nonfatal MI 1.53 0.001
All-cause mortality 1.49 0.02
P Philips et al. (17) 7,344 8 CHD incidence 1.32 (RO)† 1.18–1.47 0.0001 UK/W/SC M 1978–1980 NA
12,845 7 CHD death 1.15 (RO)‡ 1.07–1.23 0.0001 U.S. M 1973–1976 NA
7,992 12 1.14 (RO)§ 1.05–1.25 0.003 U.S. M NA
P Kannel et al. (18) 1,393 (M) 12 CHD events 3 (M)¶ 0.001 U.S. M/F NA NA
1,401 (F) 2 (F)¶ NS
P Gillum et al. (19)f 6,196 13.9 CHD incidence 1.31 for CHD incidence 1.07–1.61 (M) U.S. M/F 1971–1975 6,100 vs. 8,100
(CHD mortality) CHD death 1.05–1.63 (F)
5,293 CVD death
(CHD incidence) All-cause mortality
P Weijenberg et al. (23) 884 5 CHD incidence 1.14 0.98–1.32 Netherlands M 1985 7  109/l vs. 6.6  109/l
CHD death 1.32 1.13–1.53
P Folsom et al. (20)g 14,477 5.2 CHD incidence 1.13 (M) 0.98–1.31 (M) U.S. M/F 1987–1989 6,200 vs. 6,900
1.45 (F) 0.86–2.44 (F)
P Lee et al. (21) 13,555 8 CHD incidence 1.8 (overall) 1.32–2.43 0.001 U.S. M/F 1987–1989 4,800 vs. 7,000
1.69 (whites) 1.13–2.53 0.001
1.91 (blacks) 1.19–3.09 0.009
P Lee et al. (21) 13,555 CHD mortality 2.26 (blacks) 1.38–3.72 0.001
2.22 (whites) 1.13–4.37 0.001
P Brown et al. (22) 8,914 17 CVD mortality 1.4 1.1–1.8 1.1–1.8 U.S. M/F 1976–1980 7.7  109/l vs. 18.4  109/l
P Aronow et al. (24) 880 NA MI incidence 1.136 (OR) 1.049–1.231 0.002 U.S. NA NA NA
CC Friedman et al. (25) 464 1.4 MI incidence 1.6 0.001 U.S. M/F 1964–1970 6,300 vs. 8,800
CC Manttari et al. (26) 420 5 CHD incidence 1.13 (OR) 1.00–1.27 0.03 Finland M/F NA NA
3.07 (nonsmokers) 2.23–8.19
1.86 (smokers) 0.81–4.28
R Kostis et al. (31) 573 NA CAD incidence NA NA 0.0005 U.S. M/F NA 7,280 vs. 6,664
R Takeda et al. (27) 6,021 NA ACS incidence 2.049 1.042–4.016 0.038 Japan M/F 1994–1999 9,209 vs. 6,205
MA Danesh et al. (5)# 7,229 8 MI incidence
 CHD mortality
1.5 1.4–1.6 NA NA M/F NA 8.4  109/l vs. 5.6  109/l
*Risk estimate is given in terms of relative risk, except where the relative odds (RO) or odds ratio (OR) is indicated. †British Regional Heart Study (BRHS). ‡Multiple Risk Factor Interventional Trial I (MRFIT I). §Multiple Risk Factor
Interventional Trial II (MRFIT II). ¶Relative risk of coronary heart disease (CHD) incidence determined by comparing lowest leukocyte count tertile with highest leukocyte count tertile. For each 1,000/l increase in leukocyte count.
#Meta-analysis by Danesh et al. yielding overall relative risk and 95% confidence interval (CI) in all prospective and prognostic studies. fValues for CHD death and all-cause mortality have not been mentioned. gValues after an increase
of 1 SD in leukocyte count.
ACS  Acute coronary syndrome; CAD  coronary artery disease; CC  case-control; CVD  cardiovascular disease; MA  meta-analysis; MI  myocardial infarction; NA  not applicable; NS  not significant; P  prospective;
R  retrospective; S  Scotland; W  Wales.
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Table 2. Studies Correlating Leukocyte Count and Coronary Heart Disease in Subjects With Acute Myocardial Infarction or Unstable Angina
Study
Type Study (Ref.)
Sample
Size
Follow-Up
(yrs) Clinical End Points Risk† 95% CI p Value Setting Gender Years of Enrollment
Leukocyte Count
Cutoff Values
P Amaro et al. (30) 152 3.15 Gensini index 0.05 Spain M 1985–1990 8,309 vs. 7,548
CHD death
P Hajj-Ali et al. (32) 1,294 2.1 RI/CHD death 1.18 1.00–1.40 0.05 U.S./Canada M/F 1983–1986 52,000 vs. 10,600
P Hajj-Ali et al. (32) 1,294 2.1 AMI/death 1.26 1.08–1.47 0.003 U.S./Canada M/F 1983–1986 52,000 vs. 10,600
P Furman et al. (34) 2,863 4 Post-AMI mortality 1.65‡ 1.09–2.49 U.S. M 1986, 1988, 1990–1991 7,900 vs. 14,200
P Cannon et al. (35) 10,288 0.8 AMI, recurrent ischemia 2.38 (30 days)§ 0.001 U.S./UK F 1997–1998 6,000 vs. 10,000
1.85 (10 months)§ U.S./UK
P Cannon et al. (35) 10,288 0.8 CHD death 5.2 (30 days)¶ 0.001
3.5 (10 months)¶
P Barron et al. (36) 153,213 NA CHD death 2.37 (OR) 2.25–2.49 0.0001 U.S. M/F 1994–1995 6,000 vs. 12,000
2,208 0.5 Death, nonfatal MI 4.3 (HR)
P Sabatine et al. (37) ACS 0.049 U.S. M NA NA
P Mueller et al. (38) 1,391 1.4 CHD death 3.3 (HR) 1.94–5.58 0.001 Switzerland M/F 1996–1999 6,800 vs. 10,000
CC Hung et al. (39) 36 2.3 CHD death NA NA 0.005 Taiwan M/F 1998–2002 6,650 vs. 10,100
R Barron et al. (40) 975 NA Death/CHF/shock* 0.24 (death) 0.07–0.75 0.014 U.S. M/F NA NA
0.24 (CHF/shock) 0.08–0.74 0.01
0.19 (death/CHF/shock) 0.07–0.47 0.001
P Zouridakis et al. (43) 71 1.1 UA/MI/CHD death 5.9 (OR) 1.03–33.65 0.041 UK M/F 1996–1997 2.40  109/l
R Ommen et al. (47) 211 3.75 CHD mortality 1.8# 0.04 U.S. M/F 1981–1985 NA
*All values are for the highest leukocyte count tertile. †Risk is given in terms of relative risk, except where the RO, OR, or hazard ratio (HR) is indicated. ‡OR for the highest leukocyte quintile. §Leukocyte count 10,000. ¶Leukocyte
count 15,000. Ratio with 10-U decrease of lymphocyte count. #Odds ratio for individuals with lymphocyte counts lower than the cut-off value.
AMI  acute myocardial infarction; CHF  congestive heart failure; RI  reinfarction; UA  unstable angina. Other abbreviations as in Table 1.
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November 16, 2004:1945–56 Leukocyte Count and CHDusion, more extensive CAD, and higher six-month mor-
ality. In a study that stratified patients with non–ST-
egment elevation acute coronary syndrome and Braunwald
lass IIB or IIIB UA into quartiles by leukocyte count (38),
hose patients in the highest quartile were 3.3 times more
ikely to die of cardiac causes than those in the lowest
uartile. Moreover, in a case-control study of patients with
cute MI (39), leukocyte counts were significantly higher in
atients who died of cardiac causes than in those who did
ot.
A number of retrospective studies have been conducted in
atients with acute MI or unstable angina. The TIMI-10A
nd -10B trials (40) found that relatively high leukocyte
ounts were associated not only with new-onset congestive
eart failure or shock but also with higher mortality rates. In
study assessing the sensitivity and specificity of leukocyte
ounts for disease in patients whose echocardiograms were
on-diagnostic (41), baseline total creatine kinase (CK),
K-MB fraction, leukocyte count, and absolute neutrophil
ount were relatively insensitive (39%, 73%, 35%, and 36%,
espectively) but relatively specific (94%, 93%, 85%, and
6%, respectively) as prognostic markers. In a logistic
egression model, leukocytosis was an independent predic-
or of acute MI. Moreover, a combined decision rule of
ither elevated CK-MB or elevated leukocyte count was
8% sensitive and 79% specific, whereas a combined deci-
ion rule of both elevated CK-MB and leukocyte count was
0% sensitive and 99% specific. Table 2 lists these studies.
IFFERENTIAL LEUKOCYTE COUNT AS A
ISK FACTOR AND PROGNOSTIC INDICATOR
he utility of differential leukocyte counts as a risk marker
as been evaluated in a number of studies (Table 3). In the
iroshima and Nagasaki Adult Health Study (3), the total
eukocyte count correlated positively with the incidence of
HD in a large population of individuals free of disease at
aseline. When differential cell counts were considered, a
orrelation was found between moderately elevated eosino-
hil count and increased risk of disease, as well as between
eutrophil, eosinophil, and monocyte (but not lymphocyte)
ounts and the incidence of disease. The Paris Prospective
tudy II (4) revealed that, after adjustment for other
ariables, the risk of CHD increased 1.15 times for each
ncrease of 100 cells/mm3 in monocyte count. In two studies
rom the United Kingdom (42), the age-adjusted relative
dds of CHD were highest for those men with the highest
eukocyte counts; in fact, these odds were more than twice
hose for neutrophils, eosinophils, lymphocytes, monocytes,
r basophils. In addition, a positive correlation was seen
etween neutrophil and eosinophil counts and disease inci-
ence, but not between lymphocyte, monocyte, or basophil
ounts and disease incidence.
Prospective studies have shown that the inflammatory cell
ctivity and leukocyte count may be useful prognosticindicators in patients with acute MI or UA. In a one-yearTa
b
St
u
T
y P P P
*R
is C
f
t
l
w
h
o
a
t
m
p
(
f
w
(
M
0
p
c
i
c
w
l
n
l
a
p
s
c
(
h
p
(
c
a
w
a
a
w
d
t
p
a
P
L
T
m
(
t
q
P
m
a
a
p
o
p
r
B
a
s
r
a
a
f
t
i
a
c
a
d
a
c
o
V
m
t
s
l
p
c
l
m
i
A
r
m
a
A
a
g
r
w
a
p
T
A
E
V
D
A
E
I
A
A
E
I
I
I
C
1950 Madjid et al. JACC Vol. 44, No. 10, 2004
Leukocyte Count and CHD November 16, 2004:1945–56ollow-up study of patients with UA (43), patients who had
he highest leukocyte counts were roughly eight times more
ikely to have a major cardiovascular event than patients
ith the lowest counts and were five times more likely to
ave one than all other patients. In a large prospective study
f patients who underwent coronary artery bypass grafting
nd were stratified by preoperative leukocyte count (44),
otal mortality was 2.6% (294 of 11,270); the adjusted
ortality, however, was almost three times higher for
atients with the highest versus lowest leukocyte quintiles
12.0  109/l vs. 6.0  109/l). Other evidence comes
rom the study by Erdogan et al. (45) in which the authors
ere able to find elevated levels of serum immunoglobulin E
p  0.002), basophils (p  0.02 and p  0.012 for acute
I and UA patients, respectively) and eosinophils (p 
.005) in the patients diagnosed with acute MI, UA
ectoris, and stable angina pectoris, compared with healthy
ontrol subjects.
Several retrospective and case-control studies have exam-
ned the relationship between total and differential leuko-
yte counts and CAD. In a retrospective study of patients
ho underwent coronary angiography (46), both the total
eukocyte count and band neutrophil count correlated sig-
ificantly with coronary atherosclerosis, although the corre-
ation with total leukocyte count lost significance after
djustment for other risk factors. One retrospective study of
atients with CAD (47) showed that five-year survival was
ignificantly better for patients who had a normal as
ompared with a low (20.3%/l) relative lymphocyte count
92% vs. 83%). Several studies of patients with congestive
eart failure have identified a low lymphocyte count or low
ercentage of lymphocyte as an adverse prognostic factor
see the subsequent text). In a small case-control study
omparing patients with vasospastic angina pectoris, stable
ngina, and no angina (controls) (48), eosinophil counts
ere significantly higher in those who had severe vasospastic
ngina pectoris than in those who had mild vasospastic
ngina pectoris, stable angina, or no angina. After treatment
ith anti-anginal drugs, however, the eosinophil counts
ecreased to control levels. Maseri et al. (49) have reported
hat the number of neutrophils was much higher in the
atients with acute MI than in those with UA or stable
ngina.
OSSIBLE MECHANISMS OF ACTION OF
EUKOCYTES IN CHD
he possible biologic mechanisms by which leukocytes
ight influence the development of CHD are protean
Table 4). They include biochemical, biomechanical, hema-
ologic, and electrical mechanisms of action and are subse-
uently discussed in more detail.
roteolytic and oxidative vascular damage. Leukocytes
ay influence the development of CHD through their
bility to cause proteolytic and oxidative damage to coronary
rteries. Stimulated neutrophils are known to: 1) secrete broteolytic neutral proteases that promote the detachment
f endothelial cells from vessel walls and the adherence of
latelets to subendothelial collagen and fibronectin (50); 2)
elease large amounts of the chemotactic agent leukotriene
4 in patients with stable angina (51); 3) secrete large
mounts of inflammatory mediators (52); and 4) release
uperoxide anions in hyperlipidemic patients (53). Some
esearchers have observed increased neutrophil aggregation
nd oxidase activity in the coronary sinuses of patients with
ngiographically documented CAD (54). Even observations
rom cancer research argue for this mechanism: the endo-
helial injury caused by leukostasis in patients with leukemia
s apparently due to an overabundance of leukemic cells that
ctivate adhesion molecules and to the migration of these
ells into perivascular spaces (55). Oxygen-free radicals play
n important role in the atherosclerotic process, but their
estructive effects can be prevented, at least in theory, by
ntioxidant enzymes such as superoxide dismutase and
atalase (56). Proteolytic enzymes are another likely source
f arterial damage.
essel plugging. Leukocytes may influence the develop-
ent of CHD through their ability to affect blood flow
hrough the cardiac microvasculature. Because they are
tiffer and larger than either red blood cells or platelets,
eukocytes may obstruct small nutrient vessels (57,58). In
atients with acute MI, the leukocytosis that follows ne-
rotic injury usually (although not always [59]) renders
eukocytes less deformable and less able to pass through the
icrovasculature, thus aggravating ischemia, extending the
nfarct area, and leading to further complications (60,61).
dhesion molecules on leukocytes become up- or down-
egulated in atherosclerosis, hence increasing chemotaxis of
onocytes beneath the endothelium in early stages of
therosclerosis (62).
bnormal leukocyte aggregation. Abnormal leukocyte
ggregation may play a role in CHD. Similar to platelets,
ranulocytes aggregate when stimulated and so may theo-
etically block microvessels (61,63). As shown in patients
ith peripheral vascular disease, increased platelet number
nd activity, neutrophil count, and acute-phase reactant
rotein levels correlate with increased plasma, serum, and
able 4. Possible Mechanisms of
ction of Leukocytes in Coronary Heart Disease
ndothelial cell injury caused by proteolytic enzymes (50–54,56)
essel plugging (61)
ecreased perfusion (40)
bnormal leukocyte aggregation (51,63)
ffects on blood flow (57,58)
ncreased expression of monocyte tissue factors (80)
ctivation of coagulation system (77,82)
ssociation with atherosclerotic risk factors (77,86–88)
lectrical instability (85)
ncreased thrombus formation in CHD (81)
nvolvement in hematologic stress syndrome (66)
ncreased leukocyte adhesion in CAD (62)
AD  coronary artery disease; CHD  coronary heart disease.lood viscosity (64), and mononuclear leukocytes become
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November 16, 2004:1945–56 Leukocyte Count and CHDess filterable during periods of ischemic pain (65). Abnor-
al leukocyte aggregation and high leukocyte counts may
ven be seen as a manifestation of hematologic stress
yndrome (66), which some have argued represents a non-
pecific response to atherosclerosis (64).
eukocytes and infarct expansion. Leukocytes may influ-
nce the development of CHD by causing infarct expansion
67,68). During reperfusion of ischemic myocardium, neu-
rophils and platelets can plug capillaries in the coronary
icrocirculation, resulting in the no-reflow phenomenon,
entricular arrhythmia, loss of coronary vascular reserve,
nfarct extension, and even organ dysfunction (69–71). The
ascular obstruction may be partly due to the binding of
eutrophils to ischemic endothelia via integrins such as
D18B and adhesion molecules such as intercellular adhe-
ion molecule (ICAM)-1. Support for this idea comes from
he observation that treatment with CD18 antibodies can
educe infarct size (72,73), as well as the observation that a
eficiency in either CD18 or ICAM-1 can markedly reduce
eutrophil accumulation and myocardial necrosis after MI-
eperfusion injury (74).
The mechanism of action underlying neutrophil-induced
nfarct expansion remains unclear. Perhaps reperfusion fur-
her inflames areas that are already ischemic, resulting in the
ccumulation of neutrophils that then worsen the existing
yocardial damage by unleashing more destructive oxygen-
erived free radicals, proteases, and leukotrienes. This view
s borne out by experimental studies showing the cardiopro-
ective effects of neutrophil inhibition (75) and the interfer-
nce of monoclonal antibodies in interactions between
eukocytes and endothelium (76).
eukocytes and hypercoagulability. Another way that
eukocytes may influence the development of CHD is by
nducing a state of hypercoagulability in response to acute
I and subsequent reperfusion. Indeed, the leukocyte count
orrelates positively with coagulation factors, including fi-
rinogen and factors VII and VIII (77). It is also known that
he systemic inflammatory response that usually follows
uccessful reperfusion involves the expression of cytokines
interleukin [IL]-1-beta, IL-8, and IL-6) and adhesion
olecules (macrophage adhesion molecule [MAC]-1) on
irculating monocytes, which in turn leads to increased
onocyte procoagulant activity (78–81). Both IL-6 and -8
xert their procoagulant effects in a time- and dose-
ependent fashion and at concentrations found in the
eripheral blood of patients with acute MI (80). MAC-
—a beta2 integrin that mediates the adhesion of leukocytes
o vessel walls, catalyzes the conversion of factor X to factor
a and binds fibrinogen (82)—may mediate the adherence
f activated platelets to neutrophils and any thrombosis that
ay follow.
eukocytes and reperfusion. The leukocyte count imme-
iately after a coronary event may influence the chances of
uccessful reperfusion. One study of patients undergoing
hrombolytic therapy after an acute MI (83) found that
hose with higher non-neutrophil counts at presentation lchieved successful reperfusion (i.e., TIMI flow grade 3)
ore often. However, this observation may be due to the
act that a longer time from symptom onset to treatment
as associated with a higher neutrophil count and a lower
on-neutrophil count, and this delay in treatment has
ffected the response to reperfusion. In general, an increased
eukocyte count immediately after acute MI has been
ssociated with poorer myocardial reperfusion, higher mor-
ality, increased risk of new-onset CHF or shock, throm-
oresistance, and greater thrombus burden (40). The in-
reased thromboresistance may be due to the enhanced
eneration of thrombin at sites of vascular injury by circu-
ating monocytes and neutrophils that have been recruited
o such sites (84). The enhanced thrombin production is
ediated by interactions between P-selectin glycoprotein
igand-l expressed by leukocytes and P-selectin expressed by
ctivated platelets and by the monocytes themselves. These
nteractions make the membrane surface available for the
ssembly and function of coagulation complexes involved in
issue factor-initiated thrombin production.
eukocytes and electrical instability. Leukocyte counts
ay affect the electrical stability of the heart. At least one
tudy has shown that a high leukocyte count is a significant
redictor of ventricular fibrillation in patients who have
uffered an acute MI (85).
eukocytes and other risk factors of CHD. The associa-
ions between leukocyte counts and other risk factors for
HD, especially smoking, have been evaluated in a number
f studies. The leukocyte count has been shown to correlate
ositively with cigarette smoking, serum total cholesterol,
erum triglycerides, clotting factors, hematocrit, fasting
lucose levels, and diastolic blood pressure (77,86–88) and
nversely with serum high-density lipoprotein cholesterol,
orced expiratory volume, forced vital capacity, and height
77,86,87). The interdependence of leukocyte count and
moking remains unclear, as the WBC count is usually
igher in smokers (Table 5). However, the WBC count has
een shown to be an independent predictor of CHD in
ultivariate analyzes adjusting for other risk factors, includ-
ng smoking in different population (Table 6).
eukocytes and body mass index (BMI). There is increas-
ng evidence suggesting a relationship between obesity and
nflammation. A higher BMI is associated with higher
erum C-reactive protein (CRP) concentrations in both
hildren and adults (89,90). New findings suggest a state of
able 5. Studies Reporting a Significant Association Between
eukocyte Count and Smoking
Study (Ref.) p Value
alokar et al. (15) 0.01
annel et al. (18) 0.01
ostis et al. (31) 0.035
reidman et al. (25)* NA
One-third of cases were due to risk factors independent of smoking. NA indicates
hat such data were not mentioned in the original report.ow-grade systemic inflammation in overweight and obese
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Leukocyte Count and CHD November 16, 2004:1945–56ersons. Brown et al. (22) reported a higher BMI (26.2 vs.
5.3 kg/m2) in persons with a WBC count7.6 109/l, as
ompared with those with a WBC count 6.1  109/l.
argher et al. (91) found a positive relationship between the
BC count and BMI. Nakanishi et al. (92) reported higher
BC counts in subjects with an increased BMI (6.64 vs.
.52 109/l for BMI 25 and 25 mg/kg2, respectively; p
0.023). Kullo et al. (93) showed that persons with a BMI
30 kg/m2 had a higher WBC count than those with a
MI 25 kg/m2 (WBC count  5.86 vs. 5.26  109/l,
espectively; p 0.05). Huang et al. (94) reported a positive
nd significant relationship between the total WBC, neu-
rophil, lymphocyte, and monocyte counts with smoking
nd BMI (p  0.001). Schwartz et al. (95), in National
ealth And Nutrition Examination Survey (NHANES) II,
howed that BMI is a significant predictor of elevated WBC
ounts (beta  0.53, p  0.001). The Helsinki Heart Study
26) was an exception that did not show a significant
elationship between WBC counts and BMI (beta  0.06,
 0.2).
eukocytes and heart failure. The leukocyte count ap-
ears to be a predictor of heart failure. In the TIMI-10A
nd -10B thrombolysis trials (40), high leukocyte counts
ere significantly associated with the development of new
HF or shock, even after adjustment for potential con-
ounding variables in a multivariate model. High leukocyte
ounts have also been associated with the development of
eart failure and one-year mortality in patients with MI
33). However, in patients with chronic CHF, a low
ymphocyte count or low percentage of lymphocytes predicts
eath. This belief is strengthened by the study by Omen et
l. (47). They found that one- and four-year survival rates
ere 90% and 73% in patients with normal lymphocyte
ounts versus 78% and 34% in patients with lower lympho-
yte counts. Acanfora et al. (96) evaluated the relationship
etween lymphocyte count and end points of total mortality
able 6. Studies Reporting Leukocyte Count as an Independent
isk Factor
Study (Ref.) p Value 95% CI
rimm et al. (16) 0.09
hillips et al. (17)
BRHS 0.0001
MRFIT I 0.0001
MRFIT II 0.003
eijenberg et al. (23) 1.15–1.51
ee et al. (21)
Whites 0.001
Blacks 0.009
rown et al. (22) 1.1–1.8
anttari et al. (26) 0.03
owe et al. (29) 0.001
ajj-Ali et al. (32) 0.003
maro et al. (30) 0.0001
weetnam et al. (42) 0.0001
RHS  British Regional Heart Study; CI  confidence interval; MRFIT 
ultiple Risk Factor Intervention Trial.nd cardiovascular mortality. The three-year mortality rate Pas found to be 64% in persons with a lymphocyte count
20% versus 40% in those with a lymphocyte count of
20% (p  0.0001). The multivariate adjusted hazard ratio
f mortality was found to be 1.73 (95% confidence interval
CI] 1.21 to 2.48, p  0.0026).
ther blood cell types and CHD. Although our review so
ar has focused on the relationships between leukocyte count
nd CHD, other blood cell counts and measurements
ppear to correlate with risk as well. The erythrocyte count
as been shown to correlate with carotid atherosclerosis
97), coronary artery stenosis (31), and disease severity (31).
ematocrit has been shown to correlate with carotid ath-
rosclerosis (97), coronary insufficiency (98), CHD inci-
ence (18), MI incidence (98), and CHD mortality
99,100). Blood viscosity has been shown to correlate with
arotid atherosclerosis (97) and disease mortality (99,100).
lthough the platelet count does not appear to predict
ardiovascular outcomes (20,101,102), a larger platelet size
ay correlate with CAD (101) and MI (103).
ystemic markers of inflammation and atherosclerosis. There
re no data that inflammation, as evident from leukocytosis,
s the cause or effect of the disease. Future studies are
eeded to answer this question. Emerging evidence suggests
hat serum markers of inflammation may be important
redictors of CHD. The erythrocyte sedimentation rate has
ong been known to be an independent predictor of CHD
104). Indeed, baseline plasma levels of CRP strongly
redict the risk of future cardiovascular events in apparently
ealthy subjects (105,106) and independently predict recur-
ent events and mortality in patients with acute coronary
yndrome (107–109). In a long-term study in healthy men,
aseline levels of IL-6 predicted the incidence of MI (110).
he IL-18 serum levels predict death in cardiovascular
atients (111). Serum amyloid A has been shown to be
ssociated with a higher rate of recurrent coronary events in
table patients who have had an acute MI (107,112) and to
redict a poor outcome in patients with UA (113). At the
oment, one of the most attractive candidate markers of
ardiovascular outcome is CRP (114). It appears to be a
trong predictor of CHD and is now being used in clinical
ssessment of CHD risk (115). When combined with the
idely available and inexpensive leukocyte count, CRP may
ield additional information on the risk and prognosis for
atients with UA or MI (37).
LINICAL IMPLICATIONS
he leukocyte count has been consistently shown to be an
ndependent risk factor and prognostic indicator of future
ardiovascular outcomes, regardless of disease status. In
atients with a history of CVD, it is an independent
redictor of future events. Moreover, the leukocyte count is
nexpensive, reliable, easy to interpret, and ordered routinely
n inpatient and outpatient settings. However, when we
urveyed 100 randomly selected studies (available on
ubMed) of CHD risk assessment, diagnosis, or prognosis,
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November 16, 2004:1945–56 Leukocyte Count and CHDhe leukocyte count as a risk factor was mentioned in only
wo studies. The relative lack of attention in research studies
as understandably reflecting the interest of investigators in
olecular mechanisms and the industry’s interest in new
ssays.
MPLICATIONS FOR THE STEM CELL THERAPIES
he increased risk of coronary thrombosis associated with
eukocytosis, together with the association of UA with
ctivation of circulating leukocytes, and the well-established
isk of leukocyte plugging on reperfusion raise the question
f the safety of stem cell therapies that rely on intracoronary
nfusion of leukocytes or systemic injections of granulocyte
olony-stimulating factor or granulocyte macrophage
olony-stimulating factor, which raise leukocyte counts.
hese approaches may increase the risk of thrombosis and
ay be more problematic than the small arrhythmogenic
otential of subendocardial injections.
EED FOR FURTHER TRIALS
lthough the leukocyte count appears to be an independent
redictor of cardiovascular events, some of its predictive
bility can be explained by its interdependence with smok-
ng. Therefore, further studies are needed to clarify just how
rominent a role leukocytes play in the pathogenesis of
HD, as well as the clinical implications. Obviously, there
s a need to determine the degree to which leukocyte count
s independent of smoking and other risk factors. Existing
atabases may be useful in this regard.
The most important questions are: 1) Which leukocyte
ount cutoff points will be most useful for predicting CHD
isk in clinical practice? 2) What is the relative predictive
alue of differential leukocyte counts? Which leukocyte
ubtype or subtypes (eosinophils, basophils, or neutrophils),
f any, will be most useful for predicting risk? 3) Will
ombining serum markers of inflammation (such as CRP,
ipoprotein phospholipase A2, pregnancy-associated plasma
rotein-A, and myeloperoxidase) with the leukocyte count
ncrease predictive ability (114,116,117)?
Other questions also warrant investigation. For example,
an the leukocyte count be used as a surrogate outcome in
tudies of anti-inflammatory medications? Also, of great
mportance would be identification of patient populations
hat will benefit from the test and also appraisal of the
vailable data to find the optimal timing for doing the test.
uch studies should identify the best clinical approach to
ake once these patients are found to have a high leukocyte
ount. More aggressive anti-inflammatory and general risk
actor modification treatment may be indicated in these
atients.
UTURE THERAPIES
f one or more types of leukocytes prove to have prognostic
tility independent of new markers, it would be of interestf studies of anti-inflammatory drugs for CHD (e.g., nitric
xide, statins, angiotensin-converting enzyme inhibitors,
nti-tumor necrosis factor antibodies, sirolimus, peroxisome
roliferators-activate receptors agonists, taxanes, and aspi-
in) include leukocyte counts at baseline and in response to
herapies. It is also necessary to investigate if the agents that
trictly inhibit inflammation (and specifically those that
nhibit leukocyte function), without affecting platelet func-
ion or lipid levels, are able to reduce the risk of CHD.
ONCLUSIONS
high leukocyte count is associated with increased CHD-
elated morbidity and mortality in various patient popula-
ions and clinical settings. It also appears to be an indepen-
ent risk factor, regardless of atherosclerotic disease status.
hus, it may turn out to be a less expensive and more readily
vailable risk marker than other currently available risk
actors, as well as equally informative. Further studies are
equired, however, to determine the implications of using
he leukocyte count to predict clinical risk and outcome.
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